Shire’s Natpar close to commercialization

Pharmaceutical group Shire announced in a press release that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on Natpar, a recombinant parathyroid hormone with an 84–amino-acid sequence, as an adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
(Source Shire)